Related Experiment Videos
Gentamicin therapy monitoring in seriously compromised patients
Abstract:
Gentamicin therapy was monitored in 30 patients with severe infection and other concomitant disease states. The application of the nomogram of Hull and Sarubbi [6] produced good plasma levels and disappearance of the infective agent without evidence of drug toxicity in 70% of patients. The remaining 30% did not respond satisfactorily to the treatment and showed low drug serum concentrations; and them had heavy fluid losses; when we modified their treatment, outside of the nomogram guidelines, we observed a better response. Since gentamicin distributes essentially in extracellular water, subjects who have alterations of body fluids regulation should be carefully controlled.
Insights
Gentamicin therapy monitoring in severe infections showed a nomogram effective for 70% of patients. Adjusting treatment outside guidelines improved outcomes for those with low gentamicin levels and fluid loss.
Area of Science:
- Pharmacology
- Infectious Diseases
- Nephrology
Background:
- Gentamicin is an aminoglycoside antibiotic crucial for treating severe bacterial infections.
- Optimizing gentamicin dosing is essential to maximize efficacy and minimize nephrotoxicity and ototoxicity.
- Patient factors like severe infection and concomitant diseases can alter gentamicin pharmacokinetics.
Purpose of the Study:
- To evaluate the efficacy and safety of gentamicin therapy monitored using the Hull and Sarubbi nomogram in patients with severe infections.
- To identify patient subgroups who may not achieve therapeutic gentamicin levels with standard nomogram-guided therapy.
- To explore treatment modifications for patients with suboptimal gentamicin concentrations.
Main Methods:
- Prospective monitoring of gentamicin therapy in 30 patients with severe infections and comorbidities.
- Application of the Hull and Sarubbi nomogram for initial gentamicin dosing.
- Measurement of plasma gentamicin levels and assessment of clinical response and toxicity.
- Modification of treatment regimens for non-responders based on clinical judgment.
Main Results:
- The Hull and Sarubbi nomogram achieved therapeutic gentamicin levels and clinical cure in 70% of patients without toxicity.
- The remaining 30% of patients exhibited suboptimal gentamicin serum concentrations and poor treatment response, often associated with significant fluid losses.
- Treatment adjustments outside the nomogram guidelines led to improved outcomes in the non-responding group.
Conclusions:
- The Hull and Sarubbi nomogram is effective for guiding gentamicin therapy in a majority of patients with severe infections.
- Patients with altered fluid balance or significant fluid losses may require individualized gentamicin dosing adjustments.
- Close monitoring of gentamicin levels and clinical status is critical, especially in patients with complex disease states.